http://www.nanotech-now.com/news.cgi?story_id=26982
Google Search
Web
Nanotech Now
Nanoengineering Research
The Nanotech Revolution Is Upon Us. Free
Investor Research Report.
www.WealthDaily.com/NanotechRpt
Journal of Nanoengineering and
Nanosystems
journals.pepublishing.com/jnn
Home > Press > Cheaper Drugs Now Closer to Realization with New DropArray
Technology
www.nanotech-now.com
The latest news from
around the world, FREE
Full Name
Email Address
Subscribe
Abstract:
Ads by Google
IBN's First Spin-off Company, Curiox Biosystems, to Bring DropArray to Market
Cheaper Drugs Now Closer to Realization with New DropArray
Technology
Singapore | Posted on December 17th, 2007
Our NanoNews Digest A standard laboratory tool for measuring pharmacological activity of biological
substances and performing other related tests may soon be replaced by a new
Sponsors
miniaturized bioassay that will be faster, cheaper and more efficient for scientists to use,
with new technology developed by Singapore's Institute of Bioengineering and
Nanotechnology (IBN).
The new assay, named DropArray, slashes the time needed to run certain lab tests by
over 60 per cent and reduces consumable costs by nearly 90 per cent, while maintaining
the same level of flexibility and convenience as conventional platforms.
According to IBN Team Leader Dr Namyong Kim, "Our technology has the potential to
accelerate life science, drug discovery and clinical research. Using our technology,
companies can benefit from huge savings in time and money spent on research and
development and this would have a direct impact on the cost of medication and new
drugs for the consumer."
IBN's DropArray represents a unique integration of surface chemistry and microfluidics
designed to reduce the amount of material and reagent required by up to 1,000 times,
while simultaneously cutting the reaction time by up to 10 folds, making it faster and
cheaper than standard bioassays.
Each DropArray chip comprises a small (1 inch by 3 inch) flat rectangular patterned glass
slide, with hundreds or thousands of hydrophilic glass "wells" surrounded by a
hydrophobic coating. These chips can be used for common laboratory processes such as
the heterogeneous bioassay, which is typically used by scientists in diagnostic tests to
determine how a blood sample interacts with various other substances. The "wells" act
as small test tubes in which the reagents are added, mixed and incubated, and a benchtop station automatically completes the rinsing process in heterogeneous bioassay.
Nano Market
Nano Sensors
Nano Industry
Nano News
Nanotech
Premium Products
Only the news you want
to read!
Learn More
University Technology
Transfer & Patents
Learn More
Full-service, expert
consulting
Learn More
Highly tailored
technology monitoring
service
Learn More
IBN's DropArray is able to miniaturize bioassays from 50-100 microliters down to 100
nanoliters, making it possible for researchers to conduct various cell-based tests
including cancer stem cell immunoassays that had previously been extremely challenging
with conventional technology.
Furthermore, the reduction in the volume of samples and reagents required provides
similar advantages for protein-based assays such as ELISA with limited human and
animal serum such as Human Leptin and Endostatin assays.
"This DropArray was realized through the efforts of an interdisciplinary team of
researchers, which is typical of the project-oriented research at IBN," said Prof Jackie Y.
Ying, Executive Director of IBN, one of the 14 research institutes of Singapore's Agency
for Science, Technology and Research (A*STAR). Prof. Ying was one of the youngest
professors at the Massachusetts Institute of Technology, and has received many awards
for her research in nanotechnology. She was elected to the German Academy of Natural
Scientists, Leopoldina, in April 2005 as the youngest member of the Academy.
"IBN was established less than 5 years ago with the mission to conduct exciting scientific
research with significant commercial impact. Since then, we have filed more than 420
patents, and we are delighted that our entrepreneurial research team of one chemist,
one biologist, one biomedical engineer, one mechanical engineer and one chemical
engineer has taken less than three years to develop a novel technology platform that
would contribute significantly to reducing the cost of drug development and medication.
Curiox Biosystems, the company we set up to market this technology, is IBN's first spinoff."
Subscribe to the
Forbes/Wolfe Nanotech
Report & Get 2 Free
Reports
Nanotechnology Now
Featured Books
http://www.nanotech-now.com/news.cgi?story_id=26982
Nanostart AG, the German-based world's leading nanotechnology investment company,
has invested in Curiox Biosystems, which will further develop and commercialize the
DropArray technology. Curiox will be headed by 2 IBN researchers, Dr. Kim Nam Yong, a
Korean and Singapore permanent resident who received his Ph.D. in Chemistry from the
Massachusetts Institute of Technology, and Dr. Leck Kwong Joo, a Singaporean who
received his Ph.D. in Medical Sciences from the Australian National University.
For Nanostart AG, the investment in Curiox marks its first in Asia, and is of strategic
importance. Nanostart is investing in Curiox as the lead investor and is thus assuming an
active role with its investment managers in the ongoing development of the company,
jointly with Exploit Technologies, the commercialization arm of A*STAR.
"Our new investment holding, Curiox, is our first step into the highly promising Asian
market," explained Marco Beckmann, CEO of Nanostart AG. "Singapore has established
an outstanding position for itself in Asia in nanotechnology. Through our investment in
Curiox, we aim to directly participate in the dynamic growth of this region and to live up
to our claim of global leadership. Further investments in Asia will follow."
"We are delighted to learn that Nanostart is planning further activities including a local
office in Singapore. It would bring along a significant international network of business
contacts, and help other local enterprises in creating high value added jobs based on
home-grown, cutting-edge technologies," said Prof. Ying. She will hold a seat on the
company's board of directors along with a representative from Nanostart AG.
Nanotechnology Now
visitors receive a 10%
discount on the
Nanopolis educational
series Exploring
Nanotechnology,
Exploring Matter with
Synchrotron Light and
Exploring Matter with
Neutrons when using
this link.
The U.S. represents Curiox's largest potential market with more than 12,000 suitable
academic and government labs, which spent $14.3 billion on lab instruments,
consumables and reagents in 2005, and more than 14,000 industrial pharma and biotech
labs, which spent $37.4 billion in 2005.
####
About IBN
The Institute of Bioengineering and Nanotechnology (IBN) is a member of the Agency for
Science, Technology and Research (A*STAR). Established in March 2003, IBN is headed
by its Executive Director, Professor Jackie Y. Ying. The Institute’s mission is to establish
a broad knowledge base and conduct innovative research at the interface of
bioengineering and nanotechnology. Positioned at the frontiers of engineering, IBN is
focused on creating knowledge and cultivating talent to develop technology platforms in
the following six areas:
Delivery of Drugs, Proteins and Genes
Cell and Tissue Engineering
Artificial Organs and Implants
Pharmaceuticals Synthesis and Nanobiotechnology
Medical and Biological Devices
Bioimaging and Biosensing
For more information, please click here
Subscribe to the
Forbes/Wolfe Nanotech
Report & Get 2 Free
Reports
Nanotechnology
Global Technology
News & Analysis
for the world's
decision-makers
www.ft.com
Sub-50nm
Lithography
Lithography for
nanotechnology
and semiconductor
applications
Contacts:
Nidyah Sani
Phone: +65 6824 7005
Mobile: 65 9762 9720
nidyah@ibn.a-star.edu.sg
www.molecularimprints.com
Laura Lau (IBN)
DID: 65 6824 7040
Mobile: 65 9695 7521
Email: sslau@ibn.a-star.edu.sg
Copyright © IBN
If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely
responsible for the accuracy of the content.
Nanotech Now
Nanoengineering Research
The Nanotech Revolution Is Upon Us. Free
Investor Research Report.
www.WealthDaily.com/NanotechRpt
Journal of Nanoengineering and
Nanosystems
journals.pepublishing.com/jnn
Related News Press
Nanotechnology
Research
Cutting Edge
Infrastructure,
Great Funding Pursue Research
At NTU!
NTU-Singapore.com
Nanotechnology
Stock News
Investment e-Letter
Long & Short D
Brookstein of
Nanotechnology.com
www.Nanotechnology.com
Nanomedicine
Platypus Technologies announcing the addition of the Oris™ Cell Migration Assay –
Collagen Coated kit to its product line of cellular assays December 17th, 2007
Barnes&Noble.com
http://www.nanotech-now.com/news.cgi?story_id=26982
MIT works toward engineered blood vessels December 17th, 2007
'Nanomedicine is at the frontline of new drug delivery' December 15th, 2007
CNSI and NanoPacific Holdings, Inc. Announce a Partnership to Develop and
Commercialize Technologies Invented at the CNSI at UCLA December 14th, 2007
Announcements
Technion releases first ever nano-Bible December 17th, 2007
Piezo Beam Steering Mirror Platforms Provide Larger Angles, High Bandwidth &
Stability December 17th, 2007
New property found in ancient mineral lodestone: Latest nanofabrication methods
yield new clues about well-studied mineral December 17th, 2007
Nanotechnology & the Media: The Inside Story December 17th, 2007
Tools
Piezo Beam Steering Mirror Platforms Provide Larger Angles, High Bandwidth &
Stability December 17th, 2007
Quantum nanotoxicity December 17th, 2007
IBM Commemorates 60th Anniversary of the Transistor and Decades of Innovations
December 15th, 2007
From Children's Bladders To The iPhone December 14th, 2007
blog~nano
Building Gods
Quantum leap
Inapplicable
Intuitions
© Copyright 1999-2007 7thWave, Inc. All Rights Reserved
PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE